SNDX

Syndax Pharmaceuticals, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$9.54

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %38.5 / %30

Non-compliant assets / Total market cap %27.2 / %30

Non-compliant revenue / Total income %5.5 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.

Website

Analysis (Turkish): SNDX Hissesi Caiz mi, Helal mi? Syndax Pharmaceuticals, Inc. Katılım Analizi